Shares of BioVie Inc. (NASDAQ:BIVI – Get Free Report) were down 1.9% during trading on Wednesday . The company traded as low as $1.49 and last traded at $1.56. Approximately 175,544 shares were traded during trading, a decline of 57% from the average daily volume of 406,921 shares. The stock had previously closed at $1.59.
BioVie Stock Performance
The company has a market capitalization of $2.90 million, a PE ratio of -0.02 and a beta of 0.70. The stock’s 50 day moving average is $7.15 and its 200 day moving average is $9.96.
Institutional Trading of BioVie
Institutional investors and hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC lifted its stake in BioVie by 14,000.0% in the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock worth $28,000 after purchasing an additional 14,000 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in BioVie in the 4th quarter worth approximately $28,000. Northern Trust Corp purchased a new stake in BioVie in the 4th quarter worth approximately $34,000. Two Sigma Investments LP purchased a new stake in BioVie in the 4th quarter worth approximately $57,000. Finally, XTX Topco Ltd purchased a new stake in BioVie in the 2nd quarter worth approximately $40,000. 4.59% of the stock is currently owned by hedge funds and other institutional investors.
BioVie Company Profile
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Featured Articles
- Five stocks we like better than BioVie
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Lowe’s Builds Value for Investors: Still a Good Buy in 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Jackson Hole 2025: Fed’s Signal Could Shift Stocks Fast
- Investing in the High PE Growth Stocks
- Rocket Lab Stock: Breakout Brewing or Time for Patience?
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
